Preview

Онкоурология

Расширенный поиск

Системная альфа-радиотерапия радием-223: таргетное лечение больных кастрационно-резистентным раком предстательной железы с метастазами в кости

https://doi.org/10.17650/1726-9776-2019-15-2-134-142

Полный текст:

Аннотация

Спектр подходов к лечению кастрационно-резистентного рака предстательной железы в России включает химиотерапию (доцетаксел, кабазитаксел), ингибиторы андрогенного сигнала (абиратерон, энзалутамид) и системную альфа-радиотерапию (дихлорид радия-223). Радий-223 – радиоактивный кальциевый миметик, селективно кумулирующийся в метастатически пораженной костной ткани. В регистрационном исследовании доказано, что радий-223 достоверно увеличивает общую выживаемость и время до первого скелетного осложнения при кастрационно-резистентном раке предстательной железы с симптомными метастазами в кости у больных без висцеральных метастазов. Цель обзора – определение профиля пациентов, способных получить наибольший выигрыш от назначения системной радиотерапии, а также выделение оптимального места радия-223 в последовательности лекарственных агентов, применяемых при кастрационно-резистентном раке предстательной железы.

Об авторах

М. И. Волкова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
Россия

Мария Игоревна Волкова

115478 Москва, Каширское шоссе, 24



А. С. Ольшанская
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия

Кафедра онкологии ФДПО ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России

115478 Москва, Каширское шоссе, 24, 

117997 Москва, ул. Островитянова, 1



Список литературы

1. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720.

2. Freedland S.J., Richhariya A., Wang H. et al. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology 2012;80(2):293– 8. DOI: 10.1016/j.urology.2012.04.007.

3. Pezaro C.J., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270–3. DOI: 10.1016/j.eururo.2013.10.055.

4. Smith H.S. Painful osseous metastases. Pain Physician 2011;14:E373–403.

5. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s–49s.

6. Som A., Tu S.M., Liu J. et al. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 2012;107(9):1547–53. DOI: 10.1038/bjc.2012.436.

7. Tait C., Moore D., Hodgson C. et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014;114(6b):E70–3. DOI: 10.1111/bju.12717.

8. Evans C.P., Higano C.S., Keane T. et al. The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapynaive metastatic castration-resistant prostate cancer. Eur Urol 2016;70(4):675–83. DOI: 10.1016/j.eururo.2016.03.017.

9. Asselah J., Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: questions of choice. Can Urol Assoc J 2013;7(1–2 Suppl 1):S11–7. DOI: 10.5489/cuaj.274.

10. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467–79. DOI: 10.1016/j.eururo.2013.11.002.

11. Носов Д. А., Гладков О. А., Королева И. А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 458– 470.

12. Henriksen G., Breistol K., Bruland O.S. et al. Significant antitumor effect from boneseeking, alpha-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120–5.

13. Brechbiel M.W. Targeted alpha-therapy: past, present, future? Dalton Trans 2007;21(43):4918–28. DOI: 10.1039/b704726f.

14. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.

15. Ryan C.J., Smith M.R., Fizazi K. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapynaive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2):152–60. DOI: 10.1016/S1470-2045(14)71205-7.

16. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COUAA301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012;13(10):983–92. DOI: 10.1016/S1470-2045(12)70379-0.

17. Beer T.M., Armstrong A.J., Rathkopf D. et al. Enzalutamide in men with chemotherapynaive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017;71(2):151–4. DOI: 10.1016/j.eururo.2016.07.032.

18. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI: 10.1056/NEJMoa1207506.

19. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI: 10.1056/NEJMoa1213755.

20. Kantoff P.W., Higano C.S., Shore N.D. et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010;363(5):411–22. DOI: 10.1056/NEJMoa1001294.

21. Kairemo K., Joensuu T., Rasulova N. et al. Evaluation of alpha – therapy with radium223-dichloride in castration resistant metastatic prostate cancer – the role of gamma scintigraphy in dosimetry and pharmacokinetics. Diagnostics (Basel) 2015;5(3):358– 68. DOI: 10.3390/diagnostics5030358.

22. Sartor O., Coleman R., Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738–46. DOI: 10.1016/S1470-2045(14)70183-4.

23. Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397–406. DOI: 10.1016/S1470-2045(14)70474-7.

24. Parker C., Finkelstein S.E., Michalski J.M. et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol 2016;70(5):875–83. DOI: 10.1016/j.eururo.2016.06.002.

25. Saad F. J Clin Oncol 2016;34(suppl; abstr 5082).

26. Sartor A.O., Amariglio R., Wilhelm S. et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol 2013;31:5080.

27. Nilsson S., Cislo P., Sartor O. et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27(5):868–74. DOI: 10.1093/annonc/mdw065.

28. Parker C., Zhan L., Cislo P. et al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer 2017;71:1–6. DOI: 10.1016/j.ejca.2016.10.020.

29. Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306–16. DOI: 10.1016/S1470-2045(16)30173-5.

30. Saad F. JCO, 2015;33:abst. 5034.

31. Cookson M.S., Roth B.J., Dahm P. et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association. Available at: https://www.auanet.org/guidelines/castration-resistant-prostatecancer

32. Parker C., Gillessen S., Heidenreich A., Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:v69–77. DOI: 10.1093/annonc/mdv222.

33. Saad F., Chi K.N., Finelli A. et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9(3–4):90–6. DOI: 10.5489/cuaj.2526.

34. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer version 2.2016. Fort Washington, PA: National Comprehensive Cancer Network, 2016.

35. Basch E., Loblaw D.A., Oliver T.K. et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32(30):3436–48. DOI: 10.1200/JCO.2013.54.8404.

36. Oh W.K., Tombal B.F., Delacruz A. et al. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey [abstract]. J Clin Oncol. 2016;34:abst 10124.

37. Men Who Speak Up. It’s time to speak up about advanced prostate cancer. Bayer. Available at: https://www.menwhospeakup.com/index.php

38. Sartor O., Hoskin P., Coleman R.E. et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate 2016;76(10):905–16. DOI: 10.1002/pros.23180.

39. Maughan B.L., Luber B., Nadal R., Antonarakis E.S. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 2017;77(1):33–40. DOI: 10.1002/pros.23246.

40. Nordquist L.T., Shore N.D. Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases. Presented at: 2016 ASCO Annual Meeting; June 3–7, 2016; Chicago, IL.

41. Smith M.R., Parker C., Tombal B.F. et al. ERA 223: a phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynaive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2015;33:abstr TPS5082.

42. O’Sullivan J.M. ECC abstract 2561. Eur J Cancer 2015;51:S497–8.

43. Xofigo (radium-223 dichloride). Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG, 2016.

44. Xofigo (radium-223 dichloride). Full Prescribing Information, Bayer Health Care Pharmaceuticals Inc., Wayne, NJ, USA, 2013.

45. http://pharma.bayer.ru/scripts/pages/ru/catalog/xofigo.php

46. Morris M.J., Higano C.S., Scher H.I. et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostatespecific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): a phase 1/2a clinical trial [abstract]. J Clin Oncol 2015;33:abstr 5012.

47. Morris M.J., Loriot Y., Sweeney C. et al. Updated results: a phase I/IIa randomized trial of radium223 + docetaxel versus docetaxel in patients with castrationresistant prostate cancer and bone metastases. Presented at: 2016 ASCO Annual Meeting; June 3–7, 2016; Chicago, IL.

48. Nilsson S., Franzen L., Parker C. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587–94. DOI: 10.1016/S14702045(07)70147-X.

49. Finkelstein S.E., Michalski J.M., O’Sullivan J.M. et al. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. J Clin Oncol 2015;33:182.

50. Keizman D., Fosboel M.O., Reichegger H. et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastasesanalysis of an international multicenter database. Prostate Cancer Prostatic Dis 2017;20(3):289–93. DOI: 10.1038/pcan.2017.6.

51. Blackledge M.D., Kohl D.M., Collins D.J. et al. Assessing response heterogeneity following radium 223 administration using whole body diffusion weighted MRI. Presented at: International Society for Magnetic Resonance in Medicine 25th Annual Meeting & Exhibition. April 22–27, 2017; Honolulu, HI.

52. Shore N.D. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology. 2015;85(4):717–24. DOI: 10.1016/j.urology.2014.11.031.

53. Gillessen S., Omlin A., Attard G. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26(8):1589–604. DOI: 10.1093/annonc/mdv257.

54. Morris M.J., Sartor A.O., Vogelzang N.J. et al. Effect of radium-223 dichloride (Ra-223) on pain from US EAP [abstract]. J Clin Oncol 2015;33:abstr 160.


Для цитирования:


Волкова М.И., Ольшанская А.С. Системная альфа-радиотерапия радием-223: таргетное лечение больных кастрационно-резистентным раком предстательной железы с метастазами в кости. Онкоурология. 2019;15(2):134-142. https://doi.org/10.17650/1726-9776-2019-15-2-134-142

For citation:


Volkova М.I., Olshanskaya A.S. Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases. Cancer Urology. 2019;15(2):134-142. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-2-134-142

Просмотров: 75


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)